The research enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Inquire before buying this research at: http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=466315 .
This research features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The research is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together. Drug profiles/records featured in the research undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Scope for this research:
· The report provides a snapshot of the global therapeutic landscape of Colorectal Cancer
· The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
· The report reviews key players involved in the therapeutics development for Colorectal Cancer and enlists all their major and minor projects
· The report summarizes all the dormant and discontinued pipeline projects
· A review of the Colorectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
· Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
· A detailed assessment of monotherapy and combination therapy pipeline projects
· Coverage of the Colorectal Cancer pipeline on the basis of target, MoA, route of administration and molecule type
· Latest news and deals relating related to pipeline products
Complete research on H2 Pipeline Review of ‘Colorectal Cancer’ spread across 1511 pages at http://www.rnrmarketresearch.com/colorectal-cancer-pipeline-review-h2-2015-market-report.html .
Reasons to buy this research:
· Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
· Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
· Develop strategic initiatives by understanding the focus areas of leading companies
· Identify and understand important and diverse types of therapeutics under development for Colorectal Cancer
· Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
· Devise corrective measures for pipeline projects by understanding Colorectal Cancer pipeline depth and focus of Indication therapeutics
· Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
· Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies mentioned: 2cureX ApS, 3-V Biosciences, Inc., 4SC AG, AB Science SA, AbbVie Inc., AbGenomics International, Inc., Actinium Pharmaceuticals, Inc., Adamed Sp. z o.o., Advaxis, Inc., Advenchen Laboratories, LLC, Alchemia Limited, Allinky Biopharma, Amgen Inc., Antibe Therapeutics, Inc. Apexigen, Inc., Aphios Corporation, Aposense Ltd., Arisaph Pharmaceuticals, Inc., ArQule, Inc., Array BioPharma Inc., Astellas Pharma Inc., Astex Pharmaceuticals, Inc., AstraZeneca Plc, ATLAB Pharma SAS, AVEO Pharmaceuticals, Inc., Basilea Pharmaceutica AG, Bavarian Nordic A/S, Baxalta Incorporated, Bayer AG, BeiGene(Beijing) Co.,Ltd, BioAtla, LLC, Biocon Limited, Bionomics Limited, Bionovis SA, Biotecnol, Inc., Biothera, Inc., Boehringer Ingelheim GmbH, Boston Biomedical, Inc., Bristol-Myers Squibb Company, Burzynski Research Institute, Inc., cCAM Biotherapeutics Ltd., CCRP Therapeutics GmbH, Celator Pharmaceuticals, Inc., Celgene Corporation, Cellceutix Corporation, Celldex Therapeutics, Inc., Cellectar Biosciences, Inc., Celltrion, Inc., Celon Pharma Sp. z o.o., Chipscreen Biosciences Ltd, Cleave Biosciences, Coare Biotechnology, Inc., Cornerstone Pharmaceuticals, Inc., Critical Outcome Technologies Inc., CritiTech, Inc., CrystalGenomics, Inc., CTI BioPharma Corp., Cytune Pharma SAS, Daiichi Sankyo Company, Limited, DanDrit Biotech A/S, Deciphera Pharmaceuticals, LLC, Dicerna Pharmaceuticals, Inc., Digna Biotech, S.L., Double Bond Pharmaceutical International AB, Dr. Reddy's Laboratories Limited, EirGenix Inc., Eisai Co., Ltd., Eli Lilly and Company, Endor Nanotechnologies SL, enGene, Inc, EnGeneIC Ltd, Ensol Biosciences Inc., EntreChem, S.L., Enzo Biochem, Inc., Epirus Biopharmaceuticals, Inc., Erytech Pharma SA, Etubics Corporation, Exelixis, Inc., F. Hoffmann-La Roche Ltd., Five Prime Therapeutics, Inc., Fusion Antibodies Limited, Genentech, Inc., Genor BioPharma Co., Ltd., Genoscience Pharma, Genzyme Corporation, GlaxoSmithKline Plc, Glycotope GmbH, Golden Biotechnology Corp., Green Cross Corporation, Hadasit Medical Research Services & Development Ltd, Hanmi Pharmaceuticals, Co. Ltd., Hemispherx Biopharma, Inc., Hetero Drugs Limited, Hospira, Inc., Hutchison MediPharma Limited, iDD biotech SAS, Ignyta, Inc., immatics biotechnologies GmbH, Immodulon Therapeutics Ltd., ImmuneXcite, Inc., ImmunNovative Developments SL, Immunomedics, Inc., Immunovative Therapies, Ltd., Inbiopro Solutions Pvt. Ltd., Incanthera Ltd., Incyte Corporation, Innovent Biologics, Inc., Interprotein Corporation, Ionis Pharmaceuticals, Inc., Isofol Medical AB, ISU ABXIS Co.,Ltd., Jiangsu Hengrui Medicine Co., Ltd., Kadmon Corporation, LLC, KAEL-GemVax Co., Ltd., KaloBios Pharmaceuticals, Inc., Kancera AB, Karyopharm Therapeutics, Inc., Kura Oncology, Inc., Kyowa Hakko Kirin Co., Ltd., Laboratorio Elea S.A.C.I.F. and A, Lee's Pharmaceutical Holdings Limited, LivTech, Inc., Loxo Oncology, Inc., Mabion SA, Mabtech Limited, mAbxience S.A., MacroGenics, Inc., MedImmune, LLC, Medivation, Inc., Merck & Co., Inc., Merck KGaA, Merrimack Pharmaceuticals, Inc., Merus B.V., Millennium Pharmaceuticals, Inc., Mirna Therapeutics, Inc., MolMed S.p.A., Mologen AG, Momenta Pharmaceuticals, Inc., Morphotek, Inc., Multimmune GmbH, Mycenax Biotech Inc., Natco Pharma Limited, NatureWise Biotech & Medicals Corporation, Nektar Therapeutics, Neovacs SA, Nerviano Medical Sciences S.r.l., Nippon Kayaku Co., Ltd., NormOxys, Inc., Northwest Biotherapeutics, Inc., Novartis AG, NuCana BioMed Limited, OBI Pharma, Inc., Oncobiologics, Inc., Oncology Research International Limited, Oncolytics Biotech Inc., OncoMed Pharmaceuticals, Inc., Onconova Therapeutics, Inc., Oncothyreon Inc., Oryx GmbH & Co. KG, Otsuka Holdings Co., Ltd., Oxford BioMedica Plc, Panacea Biotec Limited, Pfizer Inc., and Pharma Mar, S.A.